



## YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

April 16, 2024

GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first nine months of the fiscal year ended March 31, 2024, before the U.S. market opens on Friday, April 19, 2024.



The Company's management will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, April 19, 2024 to discuss the financial results. Listeners may access the call by dialing the following numbers:

United States Toll Free:	1-888-346-8982
International:	1-412-902-4272
Mainland China Toll Free:	4001-201203
Canada Toll Free:	1-855-669-9657
Hong Kong:	852-301-84992

Upon dialing-in, participants should ask to be joined into the YS Biopharma Co., Ltd. call.

The replay will be accessible through April 26, 2024 by dialing the following numbers:

United States Toll Free:	1-877-344-7529
International:	1-412-317-0088
Canada Toll Free:	1-855-669-9658
Access Code:	2468327

A live and archived webcast of the conference call will also be available at the Company's investor relations website at <https://investor.ysbiopharm.com/>.

### About YS Biopharma

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit [www.ysbiopharma.com](http://www.ysbiopharma.com).

### Investor Relations Contact

Alyssa Li  
Director of Investor Relations  
Email: [ir@yishengbio.com](mailto:ir@yishengbio.com)

Robin Yang  
Partner, ICR, LLC  
Tel: +1 (212) 537-4035  
Email: [YSBiopharma.IR@icrinc.com](mailto:YSBiopharma.IR@icrinc.com)

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/ys-biopharma-to-report-first-nine-months-of-fiscal-year-2024-financial-results-on-april-19-2024-302118047.html>

SOURCE YS Biopharma Co., Ltd.